LOXL2在肝细胞癌肺转移前微环境形成中的病理意义及分子机制
该研究利用两种动物模型及模拟肺组织硬度的可调凝胶体外系统,探讨肝细胞癌释放的LOXL2促进肺转移前微环境形成及肺转移的机制。结果显示LOXL2增强肺内CD11b+/CD45+骨髓来源细胞募集和纤连蛋白表达,促进肺转移,且LOXL2高表达组患者复发率更高。靶向LOXL2诱导的肺转移前微环境可能成为抗HCC转移的新干预途径。
要点
- 肿瘤释放的LOXL2促进肺转移前微环境形成和肺转移发生。
- LOXL2所致基质硬化协同调控肺转移前微环境形成。
- 靶向LOXL2诱导的肺转移前微环境或可干预HCC转移。
核心结论
- 原发肿瘤释放的LOXL2促进肺转移前微环境形成和肺转移发生。
- LOXL2所致基质硬化协同调控肺转移前微环境形成。
- 靶向LOXL2诱导的肺转移前微环境可能是抗HCC转移的新干预途径。
研究设计与样本
- 使用两种不同动物模型和模拟肺组织硬度的可调凝胶体外系统探索LOXL2在转移前微环境形成中的机制。
- 通过尾静脉注射CM-LV-LOXL2-OE模拟肿瘤释放的可溶性因子诱导肺转移前微环境形成。
- 利用LOXL2过表达异种移植HCC模型验证肿瘤分泌LOXL2对肺转移的作用。
主要发现
- 注射LOXL2显著增强肺内CD11b+/CD45+骨髓来源细胞募集和纤连蛋白表达。
- LOXL2过表达异种移植HCC模型证实肿瘤分泌LOXL2显著促进肺转移发生。
- 体外实验中LOXL2及LOXL2所致基质硬化上调肺成纤维细胞MMP9和纤连蛋白表达,增加黏附HCC细胞数量和趋化因子CXCL12表达。
- PI3K-AKT通路激活介导LOXL2上调纤连蛋白。
- 高LOXL2组HCC患者肿瘤复发比例高于低LOXL2组。
临床怎么用
- LOXL2高表达与HCC患者更高复发比例相关,提示其可用于预后风险分层参考。
- 靶向LOXL2诱导的肺转移前微环境可能作为抑制HCC肺转移的潜在干预策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The mechanisms underlying the contribution of primary tumour to pre-metastatic niche formation remains largely unknown in hepatocellular carcinoma (HCC). We previously reported that the released LOXL2 from HCC cells under higher stiffness stimulation facilitated the formation of lung pre-metastatic niche. Here, we further clarified the pathological role of LOXL2 in promoting lung pre-metastatic niche formation and lung metastasis occurrence in HCC and its relevant molecular mechanism. METHODS: Using two different animal models and an in vitro system of mechanically tuneable gel mirroring lung tissue stiffness, we explored the underlying mechanism of LOXL2 in pre-metastatic niche formation. RESULTS: We applied tail vein injection of CM-LV-LOXL2-OEsimulating tumour-released soluble factors to induce lung pre-metastatic niche formation and found that the injected LOXL2 remarkably enhanced CD11b+/CD45+ bone marrow-derived cells (BMDCs) recruitment and fibronectin expression in lung. Subsequently, LOXL2-overexpressed xenograft HCC models validated that tumour-secreted LOXL2 significantly promoted the occurrence of pulmonary metastasis. In vitro, LOXL2 and LOXL2-caused matrix stiffening not only obviously upregulated the expressions of MMP9 and fibronectin in lung fibroblasts, but also evidently increased the number of adherent HCC cells and the expression of chemokine CXCL12. The activation of PI3K-AKT pathway mediated LOXL2-upregulated fibronectin. HCC patients in High-LOXL2 group had higher ratio of tumour recurrence than HCC patients in Low-LOXL2 group, supporting a significance of LOXL2 in HCC progression and unfavourable outcome. CONCLUSION: Primary tumour-released LOXL2 promotes lung pre-metastatic niche formation and lung metastasis occurrence. LOXL2-caused matrix stiffening synergistically regulates lung pre-metastatic niche formation. Targeting LOXL2-induced lung pre-metastatic niche may be a novel intervention approach against HCC metastasis.
引用
- Wu S, Xing X, Wang Y, et al. The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism. Eur J Cancer. 2021. PMID: 33618200. doi:10.1016/j.ejca.2021.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。